|
Oct 9
|
WuXi Biologics (Cayman) Inc (WXXWY) Half Year 2024 Earnings Call Highlights: Navigating Growth ...
|
|
Aug 30
|
WuXi Biologics Successfully Completes First Scale-Up of High-Productivity Bioprocessing Platform WuXiUI™ in 2,000L GMP Manufacturing
|
|
Aug 1
|
WuXi Biologics' Four Manufacturing Facilities and Biosafety Testing Center Certified Again by European Medicines Agency for Ten Biologics
|
|
Jan 17
|
WuXi Biologics Granted U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™
|
|
Jan 10
|
WuXi Biologics Announces Research Service Agreement with BioNTech on Discovering Investigational Monoclonal Antibodies for Developing Next-Generation Therapeutic Product Candidates
|
|
Jan 8
|
WuXi Biologics to Increase Manufacturing Capacity in Massachusetts
|
|
Dec 8
|
WuXi Biologics Awarded Highest Platinum Medal by EcoVadis Sustainability Rating
|
|
Dec 5
|
China biotech: investors fear a negative reaction from the US
|
|
Nov 8
|
WuXi Biologics Receives AAA MSCI ESG Rating
|
|
Nov 7
|
Hong Kong IPO: WuXi Biologics to spin off contract research, manufacturing unit via US$520 million deal in biotech push
|
|
Aug 11
|
WuXi Biologics and Boostimmune Sign MOU for Exclusive Research and Discovery Services
|